GoodRx (NASDAQ:GDRX) Reaches New 12-Month Low on Analyst Downgrade

GoodRx Holdings, Inc. (NASDAQ:GDRX) hit a new 52-week low on Wednesday after Citigroup lowered their price target on the stock from $10.00 to $7.00. Citigroup currently has a buy rating on the stock. GoodRx traded as low as $4.61 and last traded at $4.63, with a volume of 871841 shares traded. The stock had previously closed at $4.70.

Other equities research analysts have also issued reports about the stock. Raymond James upgraded shares of GoodRx from an “outperform” rating to a “strong-buy” rating and set a $10.00 price objective on the stock in a report on Friday, August 9th. Royal Bank of Canada reiterated an “outperform” rating and issued a $10.00 price target on shares of GoodRx in a research note on Friday, August 16th. Barclays lowered their price target on shares of GoodRx from $10.00 to $6.00 and set an “overweight” rating on the stock in a research note on Monday. Finally, UBS Group lowered their price target on shares of GoodRx from $9.00 to $8.50 and set a “neutral” rating on the stock in a research note on Friday, August 9th. One research analyst has rated the stock with a sell rating, four have assigned a hold rating, nine have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $8.86.

Insider Buying and Selling

In related news, major shareholder Equity Vii L.P. Spectrum sold 10,677 shares of GoodRx stock in a transaction dated Tuesday, September 3rd. The shares were sold at an average price of $7.86, for a total transaction of $83,921.22. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 4.17% of the stock is currently owned by insiders.

Institutional Trading of GoodRx

Institutional investors have recently bought and sold shares of the business. Rubric Capital Management LP raised its position in shares of GoodRx by 25.2% in the 3rd quarter. Rubric Capital Management LP now owns 4,680,028 shares of the company’s stock valued at $32,479,000 after buying an additional 943,226 shares in the last quarter. Dynamic Technology Lab Private Ltd raised its position in shares of GoodRx by 260.7% in the 3rd quarter. Dynamic Technology Lab Private Ltd now owns 44,419 shares of the company’s stock valued at $308,000 after buying an additional 32,104 shares in the last quarter. Charles Schwab Investment Management Inc. raised its position in shares of GoodRx by 5.8% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 480,123 shares of the company’s stock valued at $3,332,000 after buying an additional 26,262 shares in the last quarter. Quest Partners LLC acquired a new position in shares of GoodRx in the 3rd quarter valued at approximately $160,000. Finally, CWA Asset Management Group LLC acquired a new position in shares of GoodRx in the 3rd quarter valued at approximately $370,000. Institutional investors own 63.77% of the company’s stock.

GoodRx Stock Down 0.9 %

The firm’s 50-day moving average price is $6.76 and its 200 day moving average price is $7.48. The company has a market capitalization of $1.77 billion, a price-to-earnings ratio of -153.67, a PEG ratio of 3.24 and a beta of 1.39. The company has a current ratio of 5.48, a quick ratio of 5.48 and a debt-to-equity ratio of 0.70.

GoodRx Company Profile

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.